Personne :
Berthelot, William

En cours de chargement...
Photo de profil
Adresse électronique
Date de naissance
Projets de recherche
Structures organisationnelles
Fonction
Nom de famille
Berthelot
Prénom
William
Affiliation
Université Laval. Faculté de médecine
ISNI
ORCID
Identifiant Canadiana
ncf13678382
person.page.name

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • Publication
    Restreint
    Benefits-risks and impacts on quality of life of medications used in multimorbid older adults : a Delphi study
    (SpringerLink, 2019-11-13) Berthelot, William; Frini, Anissa; Lunghi, Carlotta; Laroche, Marie‑Laure; Sirois, Caroline
    Background: Multimorbidity and polypharmacy are common in older people. Despite the existence of quality criteria for medication use among this population, there is little guidance for managing the complex pharmacological arsenal in a multimorbidity context. Objective To establish consensus on benefts, risks and impacts on quality of life of medications used in an older adult with three chronic diseases that require complex pharmacotherapy. Setting International experts in pharmacology. Method: A panel of experts responded to three rounds of a Delphi survey. They assessed the benefts, risks and positive impacts on quality of life of 50 diferent medications or medication classes that could be used by a hypothetical multimorbid older patient aged 65–75 years, with type 2 diabetes, heart failure and chronic obstructive pulmonary disease. Each aspect was evaluated on a 5-level Likert scale. Main outcome measure Percentage of agreement on each of the three aspects for all medication. Results: Consensus was reached on 95% of items (166/174). Only two medication classes were associated with both the highest category of benefts and positive impacts on quality of life, and the lowest risk category: long-acting anticholinergics and long-acting beta-2-agonists. Nine other medications/classes of medications were categorized within the highest benefts level (metformin, DPP-4-inhibitors, short-acting beta-2-agonists, ACE inhibitors, beta-blockers, warfarin, non-vitamin K oral anticoagulants, nitrates and acetaminophen). Fifteen medications were included in the highest level of risks, among which warfarin and Non-vitamin K oral anticoagulants. Conclusions: Medications recommended in clinical guidelines for individual diseases are generally considered positive for multimorbid older patients. Nevertheless, a non-negligible number of medications was deemed negative or very negative by our panelists. For multimorbid patients, individualizing treatment according to their preferences seems of utmost importance.